Objective: Oral anticoagulation treatment (OAT) resumption is a therapeutic dilemma in intracerebral hemorrhage (ICH) care, particularly for lobar hemorrhages related to amyloid angiopathy. We sought to determine whether OAT resumption after ICH is associated with long-term outcome, accounting for ICH location (ie, lobar vs nonlobar). Methods: We meta-analyzed individual patient data from: (1) the multicenter RETRACE study (n 5 542), (2) a U.S.-based single-center ICH study (n 5 261), and (3) the Ethnic/Racial Variations of Intracerebral Hemorrhage study (n 5 209). We determined whether, within 1 year from ICH, OAT resumption was associated with: (1) mortality, (2) favorable functional outcome (modified Rankin Scale 5 0-3), and (3) stroke incidence. We separately analyzed nonlobar and lobar ICH cases using propensity score matching and Cox regression models. Results: We included 1,012 OAT-related ICH survivors (633 nonlobar and 379 lobar). Among nonlobar ICH survivors, 178/633 (28%) resumed OAT, whereas 86/379 (23%) lobar ICH survivors did. In multivariate analyses, OAT resumption after nonlobar ICH was associated with decreased mortality (hazard ratio [HR] 5 0.25, 95% confidence interval [CI] 5 0.14-0.44, p < 0.0001) and improved functional outcome (HR 5 4.22, 95% CI 5 2.57-6.94, p < 0.0001). OAT resumption after lobar ICH was also associated with decreased mortality (HR 5 0.29, 95% CI 5 0.17-0.45, p < 0.0001) and favorable functional outcome (HR 5 4.08, 95% CI 5 2.48-6.72, p < 0.0001). Furthermore, OAT resumption was associated with decreased all-cause stroke incidence in both lobar and nonlobar ICH (both p < 0.01). Interpretation: These results suggest novel evidence of an association between OAT resumption and outcome following ICH, regardless of hematoma location. These findings support conducting randomized trials to explore risks and benefits of OAT resumption after ICH. ANN NEUROL 2017;82:755-765 I ntracerebral hemorrhage (ICH) accounts for 10 to 20% of all acute cerebrovascular events, and it is responsible for the majority of stroke-related disability and mortality.
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Objective: Oral anticoagulation treatment (OAT) resumption is a therapeutic dilemma in intracerebral hemorrhage (ICH) care, particularly for lobar hemorrhages related to amyloid angiopathy. We sought to determine whether OAT resumption after ICH is associated with long-term outcome, accounting for ICH location (ie, lobar vs nonlobar). Methods: We meta-analyzed individual patient data from: (1) the multicenter RETRACE study (n 5 542), (2) a U.S.-based single-center ICH study (n 5 261), and (3) the Ethnic/Racial Variations of Intracerebral Hemorrhage study (n 5 209). We determined whether, within 1 year from ICH, OAT resumption was associated with: (1) mortality, (2) favorable functional outcome (modified Rankin Scale 5 0-3), and (3) stroke incidence. We separately analyzed nonlobar and lobar ICH cases using propensity score matching and Cox regression models. Results: We included 1,012 OAT-related ICH survivors (633 nonlobar and 379 lobar). Among nonlobar ICH survivors, 178/633 (28%) resumed OAT, whereas 86/379 (23%) lobar ICH survivors did. In multivariate analyses, OAT resumption after nonlobar ICH was associated with decreased mortality (hazard ratio [HR] 5 0.25, 95% confidence interval [CI] 5 0.14-0.44, p < 0.0001) and improved functional outcome (HR 5 4.22, 95% CI 5 2.57-6.94, p < 0.0001). OAT resumption after lobar ICH was also associated with decreased mortality (HR 5 0.29, 95% CI 5 0.17-0.45, p < 0.0001) and favorable functional outcome (HR 5 4.08, 95% CI 5 2.48-6.72, p < 0.0001). Furthermore, OAT resumption was associated with decreased all-cause stroke incidence in both lobar and nonlobar ICH (both p < 0.01). Interpretation: These results suggest novel evidence of an association between OAT resumption and outcome following ICH, regardless of hematoma location. These findings support conducting randomized trials to explore risks and benefits of OAT resumption after ICH. ANN NEUROL 2017; 82:755-765 I ntracerebral hemorrhage (ICH) accounts for 10 to 20% of all acute cerebrovascular events, and it is responsible for the majority of stroke-related disability and mortality. 1 Oral anticoagulation treatment (OAT) is associated with increased ICH risk, with 10 to 15% of all ICH cases occurring in the setting of therapeutic anticoagulation for prevention of cardioembolic stroke due to atrial fibrillation. [2] [3] [4] [5] Patients and clinicians are faced with a critical therapeutic dilemma in regard to OAT resumption after ICH, with increased risk of recurrent bleeding being balanced against protection from thromboembolic events. Definitive evidence is currently lacking on this topic, with current (2014) European Stroke Organization guidelines providing no specific recommendations for OAT resumption. 6 Nonetheless, ICH location is often factored in decision making, because lobar ICH (etiologically related to cerebral amyloid angiopathy [CAA]) demonstrates significantly higher recurrence rates than nonlobar ICH (caused by hypertensive small vessel disease). [7] [8] [9] Current (2015) American Stroke Association guidelines recommend avoiding OAT following lobar ICH, whereas resumption can be considered after nonlobar ICH on a case-by-case basis. 10 However, no study to date has evaluated the impact of ICH location on potential risks/benefits of OAT resumption. [11] [12] [13] [14] [15] Furthermore, published studies to date focused on the effect on OAT resumption on stroke recurrence, but failed to explore its impact on functional status outcomes of immediate relevance to patients, families, and health care providers. 14 We therefore sought to investigate whether, following lobar and nonlobar ICH, resumption of OAT for prevention of cardioembolic infarcts in the setting of atrial fibrillation is associated with functional outcome, long-term mortality, and all-cause stroke risk. We present joint analyses of individual-level data from 3 large studies of ICH: (1) the multicenter RETRACE (German-wide Multicenter Analysis of Oral Anticoagulation associated Intracerebral Hemorrhage) study of OAT-ICH conducted in Germany, 11 (2) a single-center longitudinal study of ICH conducted in Boston, Massachusetts, 7 and (3) the U.S.-based multicenter Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH) study. 16 This large collaborative effort allowed us to apply state-of-the-art statistical tools to highly curated individual-level data for a large number of consecutive OAT-ICH cases.
Materials and Methods

Participating Studies
The analyses presented include data from the 3 participating studies: (1) 
Statistical Methods
OVERALL ANALYSIS PLAN. All analyses were conducted separately for all ICH (regardless of location), nonlobar and lobar ICH; in the latter group, we conducted separate analyses for participants meeting criteria for diagnoses of possible or probable CAA. We initially conducted univariate and multivariate analyses as detailed below within each individual study dataset.
Results from multivariate regression analyses in individual studies were then meta-analyzed using a conservative inverse variance-based random effects pooling method (DerSimonianLaird). 21 Cochran Q test was used to estimate heterogeneity, followed by calculation of I 2 (percentage of effect size attributable to heterogeneity). 22 Effect size heterogeneity was considered significant for heterogeneity p values < 0.10 or I 2 > 0.20.
All effect size estimates and corresponding confidence intervals (tables and text) are derived from the aforementioned metaanalyses. p < 0.05 (2-tailed) was considered statistically significant, after adjustment for multiple testing using the false discovery rate (FDR) method as proposed by Benjamini and Hochberg. 23 All reported p values (tables and text) were adjusted for multiple testing using the FDR method. All analyses were performed with R software v3.3.1 (R Foundation for Statistical Computing).
UNIVARIATE ANALYSES. Categorical variables were compared using Fisher exact test (2-tailed) and continuous variables using the Mann-Whitney rank-sum or unpaired t test, as appropriate. We performed univariate time-to-event analyses for primary outcomes (favorable outcome, mortality, stroke recurrence) using the log-rank test. We defined favorable outcome as achieving and retaining during entire follow-up an mRS 3. We also conducted additional analyses using mRS at 1 year as an ordinal variable.
OAT RESUMPTION ANALYSES. We used multivariate logistic regression to identify variables associated with decision to resume OAT. Results from individual study-specific logistic regression models were meta-analyzed using methods described above. We sought to minimize confounding by indication in our primary analyses of long-term outcomes after OAT resumption (details below) by performing propensity score matching. We used the balanced, parallel, variable ratio (1:n) nearestneighbor approach to create clusters of matched patients for analyses. 24 Clusters were defined by pairing OAT resumption individuals with nearest-neighbor non-OAT individuals based on prespecified predictors of interest, including: (1) CHA 2 DS 2 -VASc score (subdivided by tertiles), (2) HAS-BLED score (3 or > 3), (3) admission GCS (<13,13-15), (4) discharge mRS (0-2,3, or 4-5), (5) intraventricular hemorrhage presence (yes/ no), and (6) ICH volume (dichotomized based on median values for nonlobar/lobar ICH). We also prespecified inclusion in the propensity score of all variables associated (at p < 0.10) with OAT resumption in our previously described logistic regression models. All clusters with identical propensity parameters were then collapsed to form strata for subsequent multivariate analyses of primary outcomes. Because OAT resumption was incorporated in our analyses as a time-varying covariate (see below), propensity score matching was also computed separately for each analysis interval, in a time-varying fashion. 25 PRIMARY OUTCOME ANALYSES. After propensity matching, we inspected survival and functional outcome curves using the Kaplan-Meier method. OAT resumption was defined as a timevarying covariate, indicating whether participants were exposed to therapeutic anticoagulation at each analysis time point. Multivariate modeling for mortality, favorable outcome, and stroke incidence employed propensity-adjusted Cox models. For all multivariate models, candidate covariates included all variables with p < 0.20 for association with any outcome of interest. We prespecified exposure to antiplatelet agents as a covariate of interest for initial modeling, regardless of association p values. Backward elimination of nonsignificant variables (p > 0.05) was subsequently used to generate a minimal model. The proportional hazard assumption was tested separately within each study by means of graphical checks and Schoenfeld residualbased tests. Multicollinearity was assessed by computing variance inflation factors for all variables.
SECONDARY ANALYSES. We prespecified completion of several secondary exploratory analyses as part of our study design. First, we sought to clarify whether OAT resumption was associated with early mortality (within 90 days) following index ICH. We used propensity-adjusted Cox models (as described above) investigating the association of OAT resumption before 90 days (defined as a time-varying covariate) and mortality. Second, although our primary analyses in all 3 studies extended out to 1 year after index ICH, we also conducted additional analyses with extended follow-up (beyond 1 year) in the MGH study, utilizing identical methods. These analyses included follow-up information from the first year of follow-up. Third, for lobar ICH patients with MRI-based definition of probable CAA, we tested whether presence of multiple (2) cerebral microbleeds or cortical superficial siderosis modified the association between OAT resumption and mortality/functional outcome after ICH. To do so, we repeated all multivariate analyses for probable CAA ICH survivors after inclusion of interaction terms between OAT resumption and: (1) presence of multiple (2) cerebral microbleeds and (2) presence of cortical superficial siderosis. Finally, we also conducted additional analyses using ordinal logistic regression models to explore the association between OAT resumption and mRS at 1 year as an ordinal variable. All aforementioned analyses utilized previously described methods for covariate selection and multivariate modeling described for primary outcome analyses. . These statistical differences in resumption time among individuals who were restarted on OAT were also significant when analyses were repeated separately for both lobar and nonlobar ICH (all p < 0.05). All other medical history characteristics (including CHA 2 DS 2 -VASc and HAS-BLED scores) did not differ among studies (all p > 0.20). We also compared mRS values at discharge, 3 months, 6 months, and 1 year and found no statistically significant differences across studies (all p > 0.20). Mortality rates, ICH recurrence rates, and ischemic stroke recurrence rates also did not differ across studies (all p > 0.20).
Results
Study Participants
Anticoagulation Resumption
We sought to determine factors associated with OAT resumption to perform propensity score matching in our primary analyses. We prespecified for inclusion in this analysis several parameters associated with either: (1) ICH outcome, (2) risk of hemorrhagic OAT complications, and (3) risk of stroke in atrial fibrillation. We identified discharge mRS as the only factor significantly associated with OAT resumption, and in lobar ICH only in both univariate (see Table 2 
Anticoagulation Resumption after ICH and Mortality/Functional Outcome
We subsequently examined the association between anticoagulation resumption and outcome from index OAT-ICH (Table 3) . Among nonlobar ICH survivors, 190/633 (30%) had died at 1 year from index ICH, whereas among lobar ICH survivors 123/379 (33%) were dead at 1 year. For both nonlobar and lobar ICH survivors, we found associations between OAT resumption and decreased mortality in univariate analyses; propensity-score matching confirmed these findings (see Table 3 ). OAT resumption was also associated with increased likelihood of favorable outcome, defined as mRS values of 0 to 3. Furthermore, in ordinal logistic regression analyses, we found that OAT resumption was associated with lower mRS for survivors of both nonlobar ICH (OR 5 2.36 for 1-point decrease in mRS, 95% CI 5 1.48-3.37, p < 0.001) and lobar ICH (OR 5 2.59 for 1-point decrease in mRS, 95% CI 5 1.54-3.46, p < 0.001).
A total of 17/633 (3%) nonlobar ICH survivors and 9/379 (2%) lobar ICH survivors fulfilling study eligibility criteria experienced early mortality after ICH (ie, within 90 days). We found no association between OAT resumption and early mortality for either nonlobar ICH (hazard ratio
Of note, none of the early mortality events we identified was associated with hemorrhagic or thromboembolic events (including recurrent ICH, ischemic stroke, systemic bleeding, and/or systemic thromboembolism).
All meta-analyses showed no evidence of betweenstudies heterogeneity (I 2 5 0% for all analyses, and all heterogeneity p value > 0.20). We present detailed information on 1-year mRS values by OAT resumption status in Figure 1 .
Anticoagulation Resumption after ICH and Stroke Incidence
We observed a total of 18 recurrent ICH and 58 ischemic stroke events among nonlobar ICH survivors. As presented in detail in Table 3 , OAT resumption among nonlobar ICH survivors resulted in decreased all-stroke and ischemic stroke incidence, without evidence of increased ICH recurrence. We identified 21 recurrent ICH and 27 ischemic stroke events among lobar ICH survivors. OAT resumption was associated with decreased all-cause stroke and ischemic stroke incidence in propensity-score adjusted analyses (see Table 3 ). Antiplatelet agent exposure was associated with decreased ischemic stroke risk in both lobar (HR analyses, and all heterogeneity p value > 0.20).
Long-term Outcomes and Resumption of Oral Anticoagulation
We sought to investigate whether OAT resumption was associated with outcomes of interest beyond 1 year from index ICH. To this end, we analyzed long-term followup data for 102 lobar ICH survivors and 159 nonlobar ICH survivors followed long-term as part of the MGH study. We followed lobar ICH survivors for a median of 48.6 months (IQR 5 33.9-65.4) after index ICH, during which we observed 20 recurrent ICH and 22 ischemic stroke events. Among lobar ICH survivors, OAT resumption was significantly associated with long-term functional outcome, mortality, and stroke recurrence (Table 4) . We followed nonlobar ICH survivors for a median of 46.7 months (IQR 5 32.6-63.4), during which we observed 14 recurrent ICH and 29 ischemic stroke events. OAT resumption was significantly associated with long-term functional outcome, mortality, and stroke recurrence among nonlobar ICH survivors (see Table 4 ). When compared with 1-year outcome analyses in the RETRACE and ERICH studies, none of the longterm outcome analyses showed evidence of betweenstudies heterogeneity (I 2 5 0% for all analyses, and all heterogeneity p value > 0.20).
Anticoagulation Resumption after Lobar ICH Related to Possible/Probable CAA A total of 190/379 lobar ICH survivors (50%) had available MRI data to formulate a diagnosis of possible (n 5 136) or probable (n 5 54) CAA. None of the patients' characteristics listed in Table 1 was associated with MRI data availability (all p > 0.20). OAT resumption was associated with decreased mortality and favorable outcome in both possible and probable CAA (Table 5) . Presence of multiple (2) cerebral microbleeds or of cortical superficial siderosis did not modify the associations between OAT resumption and mortality/favorable outcome after lobar ICH (all interaction p values > 0.20). Due to the limited number of strokes occurring in this subset of lobar ICH patients (11 recurrent ICH cases and 12 ischemic strokes), we opted not to perform analyses investigating the association of OAT resumption with stroke incidence.
Discussion
We presented evidence from joint analyses of 3 large observational studies, identifying for the first time associations between oral anticoagulation resumption after ICH and favorable functional outcome at 1 year. We also demonstrated evidence of association between OAT resumption and decreased all-cause stroke incidence at 1 year. Specifically, we found that OAT resumption was associated with decreased ischemic stroke risk after lobar and nonlobar ICH, but not with increased ICH recurrence risk. These findings are in contrast with currently available practice guidelines, but should not be used to directly inform treatment decisions. Instead, they provide a basis for the design of a prospective, randomized, blinded trial to definitively address this critical therapeutic dilemma. ICH location (ie, lobar vs nonlobar) represents a helpful indicator as to the underlying small vessel disease pathophysiology. 26 Nonlobar ICH has been consistently associated with hypertensive microvascular disease, whereas lobar ICH is considered a manifestation of underlying CAA. Recent randomized trial and observational data findings, however, seem to suggest that hypertension may play a role in recurrence of both lobar and nonlobar ICH. 7, 27 Nonetheless, hematoma location has consistently been associated with widely diverging risks of ICH recurrence, thus motivating the inclusion of location as a consideration for OAT resumption in current guidelines. 10 Results from our analyses, however, suggest that both lobar and nonlobar ICH survivors may benefit from OAT resumption. Even when using more sophisticated tools to separate amyloid-related from hypertension-related ICH (ie, the CAA Boston criteria), OAT resumption was still associated with decreased mortality and favorable functional outcome. These findings could be accounted for by a number of different factors. Most OAT-ICH survivors with atrial fibrillation are at higher risk for ischemic stroke than ICH recurrence, even in the lobar ICH patient subgroup (as is the case in our analyses). Interventions equally decreasing ischemic stroke risk and causing increased ICH recurrence may therefore result in a net beneficial long-term effect. It is also possible that subclinical ischemic stroke events (resulting in central nervous system additional damage and hindering recovery) are not being fully captured among ICH survivors. In turn, this could partly explain the association between prevention of thromboembolism and functional outcome. Should our findings be replicated in randomized clinical trials, additional exploration of the effects of anticoagulation on post-ICH recovery would be critical to address these issues. Our study has a number of limitations. First and foremost, the observational nature of participating studies implies the potential for bias due to confounding, and particularly for severity/indication bias. Lack of randomization in OAT resumption may have led to preferential assignment to anticoagulation of patients at higher likelihood to experience favorable outcome to begin with. Our observation of lower mRS scores at discharge for lobar ICH survivors restarted on OAT may well represent evidence of such a mechanism at play. The availability of individual-level data, however, allowed us to perform detailed analyses using specific statistical techniques to address this limitation. In particular, our propensity-score matching analyses stratified individuals based on potential predictors of favorable outcome (including discharge mRS). These analyses confirmed all unadjusted findings, thus lending support to the robustness of our conclusions. Ultimately, only a randomized clinical trial of OAT resumption after ICH would provide more definitive validation of our findings. We also utilized only a single, global measure of functional outcome after ICH, that is, the modified Rankin scale. Future studies of OAT resumption after ICH would benefit from including multiple, ideally more detailed assessments of functional outcome. 28 We also have follow-up information consistently available in all participating studies only for the first year following index ICH, thus limiting our ability to investigate the impact of OAT resumption on longerterm outcomes. However, previous studies suggest that ICH recurrence and ischemic stroke incidence rates do not increase substantially after the initial 12 months from cerebral hemorrhage, thus allowing some generalizability of our findings to lifetime risk-benefit analysis for OAT resumption. [7] [8] [9] Our long-term analyses in the MGH study were consistent with our primary analyses, as we identified persistent benefit from OAT resumption in terms of functional outcome, mortality, and stroke incidence.
Our study also displays a number of notable strengths. Our collaborative effort allowed us to analyze a large number of OAT-ICH events with in-depth clinical and neuroimaging data. Several recent studies suggested potential benefits from OAT resumption after ICH, 11, 14, 15 but were unable to address the highly relevant issue of whether ICH location (and, by extension, etiology) alters the risk/benefit balance for individual patients. Also because of collaborative efforts, statistical analyses could be performed directly on individual-level data. As mentioned above, this allowed for application of sophisticated statistical tools aimed at controlling confounding. We also gathered OAT-ICH cases from a variety of clinical settings (tertiary care academic centers, community-based academic hospitals, and community institutions) in 2 different countries with widely diverging health care delivery models, thus greatly enhancing the generalizability of our findings. Finally, we were able to investigate the association between OAT and a harmonized functional outcome metric of immediate relevance for patients and health care providers alike. All prior studies focused on binary outcomes (ie, did stroke/mortality occur or not) following OAT resumption. This approach does not take into account the severity and resulting functional impact of recurrent strokes, which can vary dramatically and are ultimately of greatest practical relevance for patients. There is increasing recognition that outcome measures in stroke research must be more patient-centered, and account for functional impact. 29 Our study represents the first exploration of these highly relevant questions among ICH survivors.
In conclusion, we present evidence from a large collaborative effort identifying novel associations between resumption of oral anticoagulation after ICH in the setting of atrial fibrillation and long-term outcomes in terms of mortality and functional status. We also found evidence of association between resumption of oral anticoagulation and all-cause stroke incidence. Because of the stated limitations, including the possibility of bias, our data do not reach the threshold of triggering a change in clinical practice. However, these results do contrast with currently available guidelines. We therefore consider additional investigations into the potential risks and benefits of OAT resumption after ICH to be high priority. Randomized clinical trials in particular are urgently needed to more accurately guide optimal decision making for these patients and their health care providers.
